Where is Allurion located?

Allurion is headquartered in Wellesley, United States.

How many employees does Allurion have?

As of Oct 31, 2026, the latest employee count at Allurion is 111.

Is Allurion a funded company?

Allurion is a funded company, having raised a total of $157M across 15 funding rounds to date. The company's 1st funding round was a $***** Series C round.

When was the latest funding round of Allurion?

Allurion's latest funding was a $***** Post IPO round on Nov 14, 2025, with participation from 0 investor.

Where does Allurion rank among its competitors?

Allurion ranks 1st amongst 8 active competitors, of which 2 are funded. It stands 1st in terms of total funding among its competitors. The most recent competitor to raise funding was Sedivention, which secured $3.41M in May, 2026.

Who are the top competitors of Allurion?

Allurion's top competitors include Apollo Endo, Sedivention and Anaxiom Corp. Among them, Sedivention secured the most recent funding round in May, 2026.

Allurion - 2026 Company Profile, Team, Funding, Competitors & Financials

Company Details

Developer of Gastric Balloon device for weight loss management. The Program targets obesity by combining a gastric balloon that occupies stomach space to promote fullness with behavioral coaching and an app for tracking progress.

Website: www.allurion.com/en-us
Social
Email ID: *****@allurion.com
Phone Number: +1 **********

Key Metrics

Founded Year

2009

Location

Wellesley, United States

Stage

Public

Total Funding

$157M in 15 rounds

Latest Funding Round

Post IPO, Nov 14, 2025, $*****

Investors

Romulus Capital & 13 more

Ranked

1^st among 8 active competitors

Employee Count

111 as on Oct 31, 2026

Similar Companies

Apollo Endo & 6 more

Exit Details

Public

View Allurion's full profile

Allurion is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
Allurion Technologies, Inc CIN: 7255311 , United States, Active		-	252 (As on Dec 31, 2023)	-

Allurion got listed on Aug 02, 2023.

Click here to take a look at Allurion's IPO in detail

Allurion has raised a total funding of $157M over 15 rounds. Allurion has 13 institutional investors and 1 angel investor.

Here is the list of recent funding rounds of Allurion:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Nov 14, 2025	9747229	Post IPO	3053312	9657554	9444795	6641978
Jan 15, 2025	4158031	Post IPO	3019281	4497787	8710179	RTW Investments
Apr 17, 2024	4980068	Post IPO	3444159	9484988	5105238	RTW Investments

Access funding benchmarks and valuations. Sign up today!

View details of Allurion's funding rounds and investors

The founders of Allurion is Shantanu Gaur.

Here are the details of Allurion's key team members:

Shantanu Gaur: Co-Founder & Co-CEO of Allurion.

View details of Allurion's Founder profiles and Board Members

Allurion's employee count trend

Allurion has 111 employees as of Oct 26. Here is Allurion's employee count trend over the years:

Uncover Allurion's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Allurion include Apollo Endo, Sedivention and Anaxiom Corp. Here is the list of Top 10 competitors of Allurion, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Allurion 2009, Wellesley (United States), Public	Developer of Gastric Balloon device for weight loss management	$157M	RTW Investments, Runway Growth Capital & 12 others	68/100
2nd	Apollo Endo 2005, Austin (United States), Acquired	Developer of therapeutic devices for obesity and other GI disorders	$80.4M	HIG BioHealth Partners, Novo Holdings & 9 others	58/100
3rd	Sedivention 2021, Munich (Germany), Seed	Developer of a minimally invasive cryo-ablation therapy for obesity. This outpatient procedure uses cryo-ablation technology to disrupt the gastric branches of the vagus nerve, permanently reducing hunger feelings. A medical device has been developed and successfully tested for safety and efficacy. The therapy aims to provide a long-term solution for weight loss, addressing a significant unmet medical need. The company is supported by several awards and investments.	$4.25M	Bmp Ventures, IBG Beteiligungsgesellschaft Sachsen-Anhalt ... & 5 others	49/100
4th	Anaxiom Corp Laguna Hills (United States), Series A	Developer of minimally invasive medical devices for obesity treatment	$5.42M	-	25/100
5th	IG Balloon 2012, Perth (Australia), Unfunded	A swallowable, nonsurgical device designed for weight loss	-	-	24/100
6th	Spatz FGIA 2005, Great Neck (United States), Funding Raised	Adjustable gastric balloons for personalized weight loss and long-term health	-	JANT Ventures	21/100
7th	Sacred Lotus 2023, Prague East District (Czech Republic), Unfunded	Developer of intragastric balloon technology for weight management	-	-	16/100
8th	Gastricballoonpill United Kingdom, Unfunded	Provider of non-surgical weight loss solutions using gastric balloon pill technology	-	-	16/100